{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:01:16Z","timestamp":1757617276392,"version":"3.44.0"},"reference-count":20,"publisher":"National Center for Global Health and Medicine (JST)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2025,8,31]]},"DOI":"10.35772\/ghm.2025.01054","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:08:58Z","timestamp":1753913338000},"page":"334-339","source":"Crossref","is-referenced-by-count":0,"title":["Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab"],"prefix":"10.35772","volume":"7","author":[{"given":"Toshimasa","family":"Shimizu","sequence":"first","affiliation":[{"name":"Departments of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Departments of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Departments of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Departments of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Morita","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yano","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hakujyujikai Sasebo Chuo Hospital, Sasebo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Kagawa University Hospital, Kagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Departments of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376:1094-1108.","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smolen JS, Breedveld FC, Burmester GR, <i>et al.<\/i> Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75:3-15.","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kawashiri SY, Shimizu T, Sato S, Morimoto S, Kawazoe Y, Sumiyoshi R, Hosogaya N, Fukushima C, Yamamoto H, Kawakami A. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments. Medicine (Baltimore). 2020; 99:e21151.","DOI":"10.1097\/MD.0000000000021151"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010; 69:1286-1291.","DOI":"10.1136\/ard.2009.121491"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015; 74:389-395.","DOI":"10.1136\/annrheumdis-2013-204016"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. Biologic discontinuation studies: A systematic review of methods. Ann Rheum Dis. 2014; 73:595-599.","DOI":"10.1136\/annrheumdis-2013-203302"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013; 310:2191-2194.","DOI":"10.1001\/jama.2013.281053"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shimizu T, Kawashiri SY, Sato S, Morimoto S, Minoda S, Kawazoe Y, Kuroda S, Tashiro S, Sumiyoshi R, Hosogaya N, Yamamoto H, Kawakami A. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments. Medicine (Baltimore). 2020; 99:e21480.","DOI":"10.1097\/MD.0000000000021480"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927; 22:209-212.","DOI":"10.1080\/01621459.1927.10502953"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guerette B, Kupper H, Redden L, Arora V, Kavanaugh A. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled OPTIMA trial. Lancet. 2014; 383:321-332.","DOI":"10.1016\/S0140-6736(13)61751-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, Brock F, Franck-Larsson K. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016; 75:52-58.","DOI":"10.1136\/annrheumdis-2014-205726"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis Rheumatol. 2017; 69:1937-1948.","DOI":"10.1002\/art.40196"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamanaka H, Nagaoka S, Lee SK, <i>et al.<\/i> Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol. 2016; 26:651-661.","DOI":"10.3109\/14397595.2015.1123349"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, <i>et al.<\/i> Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: A pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol. 2016; 68:1810-1817.","DOI":"10.1002\/art.39626"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pavelka K, Akko\u00e7 N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatol Int. 2017; 37:1469-1479.","DOI":"10.1007\/s00296-017-3749-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Filippou G, Sakellariou G, Scire CA, <i>et al.<\/i> The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: The STARTER study. Ann Rheum Dis. 2018; 77:1283-1289.","DOI":"10.1136\/annrheumdis-2018-213217"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Iwamoto T, Ikeda K, Hosokawa J, Yamagata M, Tanaka S, Norimoto A, Sanayama Y, Nakagomi D, Takahashi K, Hirose K, Sugiyama T, Sueishi M, Nakajima H. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: High predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken). 2014; 66:1576-1581.","DOI":"10.1002\/acr.22303"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Terslev L, Brahe CH, Hetland ML, <i>et al.<\/i> Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission. Rheumatology (Oxford). 2021; 60:5549-5559.","DOI":"10.1093\/rheumatology\/keab276"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nagatani K, Sakashita E, Endo H, Minota S. A novel multi-biomarker combination predicting relapse from long-term remission after discontinuation of biological drugs in rheumatoid arthritis. Sci Rep. 2021; 11:20771.","DOI":"10.1038\/s41598-021-00357-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, <i>et al.<\/i> Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS One. 2018; 13:e0192425.","DOI":"10.1371\/journal.pone.0192425"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/4\/7_2025.01054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:48:30Z","timestamp":1757134110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/4\/7_2025.01054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2025.01054","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"type":"print","value":"2434-9186"},{"type":"electronic","value":"2434-9194"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"article-number":"2025.01054"}}